Search
PATIENTS WHO MAKE RESEARCH HAPPEN
Neuroscientist Tania Gendron, Ph.D. was in her lab on Mayo Clinic's Florida campus when she received a phone call. On the line was...
FIRE IN PARADISE: MY STORY
A veterinarian tells of the long, smoke-filled hours caring for animals after the harrowing fires in California It was the night of...
ENTRADA THERAPEUTICS NABS $59M FOR DRUGS THAT GAIN “ENTRY” TO CELLS
When it comes to getting a drug into a cell, size matters. Small molecules can easily pass through the cellular membrane in a way that...
SAFETY OF TRANEXAMIC ACID DURING PEDIATRIC TRAUMA: A NATIONWIDE DATABASE STUDY*
Objectives: The present study aimed to examine the association between tranexamic acid use and adverse effects (seizures, thromboembolism,...
15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR
On Monday, Xconomy began our annual look ahead at clinical trials that could define biotech and have profound healthcare effects in...
PROCEEDINGS OF THE 3RD BEAT-PCD CONFERENCE AND 4TH PCD TRAINING SCHOOL
Abstract Primary ciliary dyskinesia is a chronic suppurative airways disease that is usually recessively inherited and has marked clinical...
RAKUTEN ASPYRIAN ENROLLING PHASE 3 TRIAL OF ASP-1929 FOR HEAD AND NECK CANCER
SAN DIEGO, Dec. 17, 2018 /PRNewswire/ - Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based...
HEALTHCARE ELIGIBILITY REPRESENTATIVE
A clinic in Sacramento is in need of a Healthcare Eligibility Representative for a long term, contract...
SOPHIRIS BIO PROVIDES UPDATES ON PHASE 2B LOCALIZED PROSTATE CANCER TRIAL
Reiterates plans to move to Phase 3 with single administration of topsalysin SAN DIEGO and VANCOUVER, British Columbia, Dec. 17, 2018...
SEER LAUNCHES TO DEVELOP LIQUID BIOPSY FOR CANCER, BRAIN DISEASE
Omid Farokhzad has, as he says, “been around the block a few times” in biotech. The cancer nanomedicine researcher has cofounded a...
15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR
It can take decades and billions of dollars to develop a drug, and its fate-and often that of its developer-rests in the outcome of...
EVOFEM BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE RESULTS OF PHASE 3 STUDY EVALUATING AMPHORA FOR HORMONE-FREE BIRTH CONTROL
Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed - Q2 2019...
DOG ADRENAL HORMONES: WHAT IS THE DIFFERENCE BETWEEN ADRENALINE AND CORTISOL?
Recently I read a great veterinary article about elevated liver enzymes in dogs. It was well written from the perspective of clinical...
TRACKING MELANOMA TO DISCOVER NEW HOPE FOR PATIENTS
This story starts with melanoma. The name of this cancer tells us it grows from skin cells called melanocytes. When these cells break,...
CANNABIS ADDICTION TREATMENT IS A SUCCESS IN CLINICAL TRIAL
The trial by Yale University included 70 men aged 18 to 55, who either got the treatment or a placebo before cutting out cannabis....
CONSUMING MORE POMEGRANATE CAN REDUCE YOUR RISK OF OBESITY-RELATED COMPLICATIONS
Pomegranate can help prevent complications linked to obesity, according to a study published in the journal Complementary Therapies...
BLACK DIAMOND EMERGES WITH $20M, AIMING FOR CANCER'S HIDDEN TARGETS
Nearly two years ago, Versant Ventures used some of its new $400 million fund to set up a drug discovery unit in Europe. The goal was...
MOTOR NEURON EXCITABILITY COULD BE REDUCED BY EZOGABINE
A recent completed clinical trial on ezogabine proved that it reduced motor neuron excitability in patients with amyotrophic lateral...